In the final segment of this 6-part HCPLive RX Review, experts discuss resmetirom’s significance and what else gives them hope for the future of MASH care.
Jeff McIntyre
Advertisement
Jeff McIntyre is the vice president of Liver Health Programs at the Global Liver Institute.
Articles by Jeff McIntyre
In the fifth segment of this 6-part HCPLive RX Review, experts discuss the evolving role of noninvasive testing in MASH care.
In the fourth segment of this 6-part HCPLive RX Review, experts discuss the continued importance of diet and exercise for managing MASH.
In the third segment of this 6-part HCPLive RX Review, experts discuss investigational therapies in the MASH pipeline and the use of combination therapy.
In the second segment of this 6-part HCPLive RX Review, experts discuss unmet needs in MASH care, even with resmetirom available as a treatment option.
In the opening segment of this 6-part HCPLive RX Review, experts reflect on resmetirom’s FDA approval for MASH and clinical challenges to implementing it.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
3
Machine Learning Model Predicts Type 2 Diabetes Risk Up To 10 Years Out
4
High-Dose Semaglutide Preserves Kidney Function, Reduces Inflammation in Obesity Without Diabetes
5